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Abstract
Background: Creutzfeldt-Jakob disease (CJD) is a rare transmissible neurodegenerative disorder. An important
determinant for CJD risk and phenotype is the M129V polymorphism of the human prion protein gene (PRNP), but
there are also other coding and non-coding polymorphisms inside this gene.
Methods: We tested whether three non-coding polymorphism located inside the PRNP regulatory region (C-101G,
G310C and T385C) were associated with risk of CJD and with age at onset in a United Kingdom population-based
sample of 131 sporadic CJD (sCJD) patients and 194 controls.
Results: We found no disease association for either PRNP C-101G or PRNP T385C. Although the crude analysis did
not show a significant association between PRNP G310C and sCJD (OR: 1.5; 95%CI = 0.7 to 2.9), after adjusting by
PRNP M129V genotype, it resulted that being a C allele carrier at PRNP G310C was significantly (p = 0.03) associated
with a 2.4 fold increased risk of developing sCJD (95%CI = 1.1 to 5.4). Additionally, haplotypes carrying PRNP 310C
coupled with PRNP 129M were significantly overrepresented in patients (p = 0.02) compared to controls. Cases of
sCJD carrying a PRNP 310C allele presented at a younger age (on average 8.9 years younger than those without
this allele), which was of statistical significance (p = 0.05). As expected, methionine and valine homozygosity at
PRNP M129V increased significantly the risk of sCJD, alone and adjusted by PRNP G310C (OR MM/MV = 7.3; 95%CI
3.9 to 13.5 and OR VV/MV = 4.0; 95%CI 1.7 to 9.3).
Conclusions: Our findings support the hypothesis that genetic variations in the PRNP promoter may have a role in
the pathogenesis of sCJD.
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Background
The polymorphism coding for methionine (M) or valine
( V )a tc o d o n1 2 9o ft h ep r i o np r o t e i ng e n e( PRNP
M129V) plays a pivotal role in the susceptibility to
Creutzfeldt-Jakob disease (CJD), influencing familial,
transmitted and sporadic forms of the disease [1]. More-
over, the PRNP M129V genotype, in combination with
the type of disease-associated prion protein (PrP
sc)
deposited in the brain, is a strong modulator of the clin-
ical phenotype of sporadic [2-6] and genetic forms [7]
and also susceptibility to variant CJD (vCJD). All vCJD
cases studied to date have been methionine homozygous
at this locus [8]. A recent genome wide association ana-
lysis performed primarily with vCJD samples showed
that PRNP locus was strongly associated to disease risk
across several markers, the main contribution being
conferred by PRNP M129V [9].
Transgenic animal models [10,11] and cattle studies
[12,13] suggest that the level of expression of PRNP has
a significant influence on the incubation period of the
disease. This finding has led to the hypothesis that var-
iations in the regulatory region of PRNP,w h i c hm a y
lead to an increased expression of the gene, may influ-
ence susceptibility and age at onset in sporadic CJD,
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vious study we defined the PRNP regulatory region, and
identified three infrequent single nucleotide polymorph-
isms (SNPs), PRNP C-101G, located upstream of the
transcription start site, and two intronic SNPs: PRNP
G310C and PRNP T385C. An initial association study
carried out in 25 sporadic CJD (sCJD) and 77 controls
showed that a subgroup that carried any of the rare
alleles in the regulatory region had an increased risk for
sCJD [14]. In addition, a subsequent genetic association
study performed on 45 sCJD and 117 controls found an
increased risk for PRNP M129V heterozygotes carrying
the PRNP -101G allele [15]. All three regulatory region
SNPs, which are within 486 bp, are included in an LD
block; pair wise LD: C-101G and G310C (D’ =1 ) ,C -
101G and T385C (D’ = 0.94), G310C and T385C (D’ =
1). Based on our initial results, we genotyped these
three PRNP regulatory region SNPs in an independent
population of 131 sporadic CJD patients and 194 healthy
controls from the UK in order to assess association with
the disease.
Methods
Cases were derived from a population-based survey of
CJD in the UK carried out by the UK National CJD Sur-
veillance Unit [16]. Those with DNA available from
1991 to 2003 were selected for the study. Only patients
with sCJD who fulfilled the WHO diagnostic criteria for
definite or probable CJD were included. Definite sCJD
diagnosis was based on neuropathological examination.
Probable cases required an appropriate clinical profile,
supported by characteristic findings on EEG or CSF 14-
3-3-protein detection [17]. Whenever possible, all EEGs
were reviewed by a member of the surveillance system
and scored for the presence or absence of typical or
characteristic diagnostic features [18]. The CSF 14-3-3
immunoassays were performed using Western-blotting
[19]. Randomly selected anonymous blood donors
formed the control group; they were collected from two
geographical areas in the UK; one in Northern Ireland
(Belfast) and one in Scotland (Edinburgh). None of the
cases or controls was included in the previous study.
Demographical and clinical data were collected for
patients. Information on PrP
sc type was included in the
database when available.
The three PRNP regulatory region SNPs and PRNP
M129V were genotyped in cases and controls as
described in a previous article [14]. Hardy Weinberg
proportions were assessed. Firstly, we tested the associa-
tion between being a carrier of the rare alleles of the
three PRNP regulatory region SNPs and the risk of
developing the disease. Odds ratios (OR) and 95% confi-
dence intervals (CI) were calculated using logistic
regression and adjusted for PRNP M129V genotype.
Secondly, using Haploview v3.2 software http://www.
broad.mit.edu/mpg/haploview we assessed linkage dise-
quilibrium (LD) between the PRNP regulatory region
SNPs and PRNP M129V; haplotype frequencies were
calculated and compared between cases and controls.
Permutation test was used in order to control for multi-
ple comparisons. Finally, we compared differences in
age at onset between CJD cases with and without the
PRNP regulatory region rare alleles associated to disease
risk. Fitting a general linear model, we assessed the dif-
ferences in age at disease onset between cases, carriers
versus non-carriers, adjusted by the molecular subtype
(the combination of PRNP M129V genotype and PrPsc
type), which is a strong modulator of age at onset [4,6].
Signed informed consent to participate in genetic
research was obtained from all controls and patients
relatives. The protocols of the studies were approved by
the local medical ethical committees.
Results
A general description of the 131 cases included in this
study is given in Table 1. There was a non-statistically
significant predominance of women. For most of the
patients
(n = 110 (84%)) the diagnosis was neuropathologically
confirmed. The molecular classification of the case
cohort showed a predominance of the MM1 subtype
(53%), corresponding to the classical disease phenotype
[4,6]. The most sensitive diagnostic test was the 14-3-3
immunoassay (90%).
One of the regulatory region SNPs (PRNP T385C)
deviated significantly from Hardy Weinberg proportions
(p < 0.001) in controls and therefore it was excluded for
haplotype analysis. PRNP C-101G, PRNP C310G and
Table 1 Overall descriptives of sporadic CJD patients (n =
131)
Characteristic
Gender: female (%) 77 (58.8)
Diagnosis classification: definite (%) 110 (84.0)
Mean age at onset (years) ± SD 65.6 ± 9.5
Mean duration of disease (months) ± SD 6.6 ± 7.0
Molecular subtype
MM1 (%) 33 (53.2)
MM2 (%) 4 (6.5)
MV1 (%) 1 (1.6)
MV2 (%) 8 (12.9)
VV1 (%) 2 (3.2)
VV2 (%) 14 (22.6)
Clinical characteristics:
Typical EEG/total EEGs (%) 50/125 (40.0)
Positive MRI/total MRIs (%) 12/28 (42.9)
Positive CSF 14.3.3 test/total tests (%) 46/51 (90.2)
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brium in the control group (p = 0.7, p = 0.4 and p =0 . 5
respectively). In the sCJD group PRNP M129V genoty-
pic distribution deviated as expected significantly (p <
0.001) from Hardy Weinberg proportions. We found
that all three SNPs were linked to PRNP M129V ( C-
101G D’ = 1; C310G D’ = 0.57; T385C D’ = 0.72).
The presence of the G allele of PRNP C-101G, or C
allele at PRNP T385C, was not associated with sCJD in
either crude or adjusted analyses. Although the crude
analysis did not show a statistically significant difference
between the proportions of PRNP 310C carriers in both
groups (OR: 1.5; 95%CI = 0.7 to 2.9; p = 0.3), after
adjusting by PRNP M129V genotype we found a signifi-
cant association between this regulatory region SNP and
the risk of sCJD. Being a C allele carrier at PRNP
G310C was significantly (p = 0.03) associated with a 2.4
fold increased risk of developing sCJD (95%CI = 1.1 to
5.4) (Table 2).
Methionine and valine homozygosity at PRNP M129V
increased significantly the risk of sCJD, in the crude
analysis (OR MM/MV = 4.3; 95%CI 2.5 to 7.2 and OR
VV/MV = 2.9; 95%CI 1.3 to 6.3) and adjusted by PRNP
G310C (OR MM/MV = 7.3; 95%CI 3.9 to 13.5 and OR
VV/MV = 4.0; 95%CI 1.7 to 9.3).
The distribution of PRNP G310C, stratified by PRNP
M129V genotypes, showed in all three strata a trend to
a higher proportion of individuals with PRNP 310C
allele in the sCJD cases than in the control group; this
difference was highest and of statistical significance (p =
0.04) in the MM group (OR = 7.2; 95%CI 0.9 to 58.8)
(Table 3). Haplotype analysis showed that combinations
carrying the wild type allele PRNP 310G coupled with
PRNP 129 M were significantly overrepresented in
cases, versus those carrying PRNP 129V which were
more common in controls, reflecting the fact that PRNP
129 M is a risk allele for sCJD. Haplotypes carrying the
mutant allele PRNP 310C were very rare (6% in cases
and 4% in controls), but when coupled with PRNP 129
M the combination was significantly overrepresented in
cases (Table 4).
When we assessed differences in the age at onset
between sCJD patients who were carriers and non car-
riers of the PRNP 310C allele, we found a statistically
significant (p = 0.05) association. Patients carrying the
PRNP 310C allele presented with disease at an earlier
age, being on average 8.9 years younger than non-car-
riers (Table 5). Table 5 shows that the decrease in age
at onset was independent of the molecular subtype. The
differences were more pronounced in the MM1 and
VV1 strata although in the latter only one patient car-
ried the PRNP 310C allele. The numbers of patients
were too low and the differences across each molecular
subtype strata were not statistically significant, but when
we tested the overall means adjusted by molecular sub-
type this difference was statistically significant (p = 0.05)
(Table 5).
Discussion
The genetics of sCJD are exceptional in that homozy-
gotes of both PRNP M129V alleles are at increased risk
of the disease. The protective effect of the PRNP codon
129 MV genotype (47.2% of the controls versus 18.3% of
cases) and the predominance of the PRNP 129 MM
Table 2 Overall distribution of PRNP regulatory region rare alleles and risk of sporadic CJD
PRNP SNP Cases (%) Controls (%) OR (95% CI) P- value OR (95% CI) * P- value*
-101G carriers 28 (22.8) 25(20.3) 0.9 (0.5-1.6) 0.64 0.98 (0.52-1.83) 0.95
-101G non carriers 95 (77.2) 98 (79.7)
310C carriers 17(13.0) 18 (9.3) 1.5 (0.7-2.9) 0.30 2.4 (1.1-5.4) 0.03
310C non carriers 114 (87.0) 176 (90.7)
385C carriers 5 (4.3) 7 (5.4) 1.3 (0.4-4.1) 0.70 0.69 (0.21-2.29) 0.54
385C non carriers 111 (95.7) 123 (94.6)
* Adjusted by PRNP M129V polymorphism
Table 3 Distribution of PRNP 310C allele, stratified by PRNP M129V genotypes, and risk of sporadic CJD
PRNP M129V genotype PRNP SNP Cases (%) Controls (%) OR (95% CI) P- value*
Methionine/methionine 310C Carriers 8 (8.2) 1 (1.2) 7.2 (0.9-58.8) 0.04
Non carriers 90 (91.8) 81 (98.6)
Methionine/valine 310C Carriers 4 (23.5) 12 (13.0) 2.1 (0.6-7.3) 0.27
Non carriers 13 (76.5) 80 (87.0)
Valine/valine 310C Carriers 5 (31.3) 5 (25.0) 1.4 (0.3-5.9) 0.72
Non carriers 11 (68.8) 15 (75.0)
*Two sided Fisher’s exact test
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the proportion of valine alleles is lower in cases (20.4%)
than in controls (33.8%), therefore in our population
PRNP 129 M is as expected a risk allele for sCJD.
There are two important findings in this study. Firstly,
we found a significant association between the regula-
tory SNP PRNP G 3 1 0 Ca n dt h er i s ko fs C J D .B e i n ga
carrier of the PRNP 310C allele increased the risk of
developing the disease 2.4 fold. However, this associa-
tion was only apparent when we adjusted for the PRNP
M129V genotype. Secondly, those patients who carried
the PRNP 310C allele presented with disease at an ear-
lier age.
In agreement with our multivariate analysis, the strati-
fied analysis of PRNP G310C across the PRNP M129V
genotypes showed a trend in all three strata to a higher
proportion of individuals with PRNP 310C allele in the
sCJD cases than in the controls. However, the MM indi-
vidual carriers of PRNP 310C presented a higher risk
than the MV and VV individuals who also carried PRNP
310C (MM group OR = 7.2 versus MV group OR = 2.1
and VV group OR = 1.4), reaching nominal statistical
significance (Table 3). Although the p-value for the
interaction term was not statistically significant in the
logistic regression model, the stratified analysis suggests
a non-additive relationship between PRNP 310C and
PRNP 129 M. An interaction between the effects asso-
ciated to the two SNPs is in line with the fact that the
PRNP 310C allele coupled PRNP 129 M is more often
found (4.4 fold) in cases than in controls, and may also
explain why the relationship between PRNP G310C and
sCJD only becomes significant after adjustment by
PRNP M129V.
W ef o u n dt h a tt h ePRNP G310C polymorphism may
influence the age at onset of disease. Patients with sCJD
carrying the PRNP 310C allele presented at an earlier
age, being on average 8.9 years younger than non-car-
riers. This difference was of borderline statistical signifi-
cance (p = 0.05). In the analysis stratified by molecular
subtypes, the highest difference in age at disease onset
between PRNP 310C carriers and non-carriers was
found in the MM1 group which would also support the
hypothesis of an interacting effect between PRNP 310C
and PRNP 129 M alleles.
Our finding of an association between the PRNP
G310C, which is a SNP located in the regulatory region
of the gene, and an increased risk and earlier age at onset
of sCJD, might suggest that the mutant PRNP 310C allele
may increase the expression of PRNP. According to the
stochastic protein conformational change theory, the risk
of developing CJD may increase proportionally with the
level of the PRNP product, the cellular prion protein
(PrP
C) available [20]. This hypothesis is in line with
experimental studies in animals. Transgenic mice models
indicate that the level of expression of PRNP determines
the length of the incubation period following inoculation
with infectious material. Mice over-expressing murine
Prnp have shorter incubation periods [10]. A similar rela-
tionship is observed in mice with decreased levels of
PrP
C. Animals with only one functional copy of murine
Prnp consistently have longer incubation periods than
wild-type mice when inoculated with the same agent
[11]. In addition, a study in inbred mice has identified
three loci on chromosomes 2, 11 and 12, that signifi-
cantly influence the incubation period. The Prnp region
in mice, located on chromosome 2, mapped for a peak
lod score of 8.2. The mice studied were all identical for
the PrP
C amino acid sequence, suggesting that the regu-
latory region of this gene may play an important role in
the length of the incubation period [21].
The molecular subtype of sCJD patients, determined
by the combination of the PrP
sc type (type 1 or 2A)
Table 4 Multilocus analysis
PRNP SNPs Frequency p-value Permutation
p-value
-101 310 129 Cases Controls
C G M 0.66 0.57 0.01 0.035
C G V 0.17 0.30 <0.001 <0.001
G G M 0.10 0.09 0.58 0.990
C C V 0.03 0.03 0.68 0.980
C C M 0.03 0.007 0.02 0.067
Table 5 Mean age at onset ± standard errors of sporadic CJD patients across molecular subtypes and PRNP 310C allele
distribution
Molecular subtype PRNP 310C carriers N PRNP 310C non carriers N Mean difference (Years) p-value
MM1 57.7 ± 8.1 2 67.9 ± 9.1 31 -10.2 0.1
MM2 - - 53.8 ± 6.9 4 - -
MV1 - - 78.1 1 - -
MV2 64.8 1 66.2 ± 5.4 7 -1.4 0.8
VV1 41.0 1 64.0 1 -23 -
VV2 64.3 ± 10.5 4 64.8 ± 11.2 10 -0.5 0.9
Overall means* 56.9 ± 3.8 8 65.8 ± 2.4 54 -8.9 0.05
* Adjusted by molecular subtype (PRNP M129V and PrP
sc type)
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of age at disease onset [4,6]. For example in our cohort,
in MM or MV type 1 cases the disease developed at age
67 years on average whereas the mean age at onset in
VV type 1 cases was 52 years (p =0 . 0 0 4 ) .D e s p i t et h e s e
trends, in all molecular subtypes except the MV1 group
(in which there were only three cases), there are cases
with symptom onset at an age of less than 50 years
(data not shown). This suggests that although molecular
subtype is an important determinant of age at onset,
there are other influencing factors. Although numbers
of cases are limited in our study, it is interesting that
within each molecular subtype, on average, carriers of
the PRNP 310C allele are younger at onset than non-
carriers.
Ap o s s i b l es o u r c eo fb i a si no u rs t u d yi st h eu s ea s
controls of randomly selected anonymised blood donors
who are not matched for age or sex with the patients.
For example, if the distribution of the genotypes studied
differed with age this would introduce bias. However, it
has been published that this is not the case and the dis-
tribution of the PRNP M129V genotypes does not differ
with gender or age [22].
Conclusion
We have partially replicated our previous study results
[14] in an independent UK case control population.
Our analyses offer new evidence for the association of
a PRNP regulatory region SNP (PRNP 310C) with risk
and earlier age at disease onset of sCJD. Although
PRNP 310C is a rare allele, and is not present in the
majority of patients with sCJD, our findings may offer
a new insight into the elusive aetiology of CJD. The
results of our study would suggest that a PRNP dosage
effect could play a role in the causal pathway of sCJD.
Nevertheless, we have to emphasize that these conclu-
sions are based on the assumption that PRNP 310 is
associated to PrP gene expression due to the fact that
it is located inside the gene regulatory region. There-
fore, functional studies to assess the effect of the
PRNP 310C allele should be carried out as a test for
this hypothesis.
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